235 related articles for article (PubMed ID: 30017201)
21. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
22. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling.
Pidugu VK; Wu MM; Yen AH; Pidugu HB; Chang KW; Liu CJ; Lee TC
Oncogene; 2019 Apr; 38(17):3232-3247. PubMed ID: 30626937
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Uzawa K; Amelio AL; Kasamatsu A; Saito T; Kita A; Fukamachi M; Sawai Y; Toeda Y; Eizuka K; Hayashi F; Kato-Kase I; Sunohara M; Iyoda M; Koike K; Nakashima D; Ogawara K; Endo-Sakamoto Y; Shiiba M; Takiguchi Y; Yamauchi M; Tanzawa H
Sci Rep; 2019 Aug; 9(1):12179. PubMed ID: 31434965
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.
Holz C; Niehr F; Boyko M; Hristozova T; Distel L; Budach V; Tinhofer I
Radiother Oncol; 2011 Oct; 101(1):158-64. PubMed ID: 21665310
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
26. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells.
van Dommelen SM; van der Meel R; van Solinge WW; Coimbra M; Vader P; Schiffelers RM
Nanomedicine (Lond); 2016 Apr; 11(8):881-90. PubMed ID: 27021928
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis.
Choi HS; Kim YK; Yun PY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360933
[TBL] [Abstract][Full Text] [Related]
29. Lewis y Expressed in Oral Squamous Cell Carcinoma Attenuates Malignant Properties
Hotta H; Hamamura K; Shibuya H; Ohmi Y; Furukawa K; Furukawa K
Anticancer Res; 2021 Apr; 41(4):1821-1830. PubMed ID: 33813387
[TBL] [Abstract][Full Text] [Related]
30. Profile of epidermal growth factor receptor (EGFr) expression in human malignancies: effects of exposure to EGF and its biological influence on established human tumour cell lines.
Nouri AM; Thompson C; Cannell H; Symes M; Purkiss S; Amirghofran Z
Int J Mol Med; 2000 Oct; 6(4):495-500. PubMed ID: 10998445
[TBL] [Abstract][Full Text] [Related]
31. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
32. Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Benhamou Y; Picco V; Raybaud H; Sudaka A; Chamorey E; Brolih S; Monteverde M; Merlano M; Lo Nigro C; Ambrosetti D; Pagès G
Oncotarget; 2016 Jul; 7(28):44236-44251. PubMed ID: 27329590
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
[TBL] [Abstract][Full Text] [Related]
34. β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma.
Chandler KB; Alamoud KA; Stahl VL; Nguyen BC; Kartha VK; Bais MV; Nomoto K; Owa T; Monti S; Kukuruzinska MA; Costello CE
Mol Omics; 2020 Jun; 16(3):195-209. PubMed ID: 32203567
[TBL] [Abstract][Full Text] [Related]
35. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
37. EGF/TGFβ1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332.
Richter P; Umbreit C; Franz M; Berndt A; Grimm S; Uecker A; Böhmer FD; Kosmehl H; Berndt A
J Oral Pathol Med; 2011 Jan; 40(1):46-54. PubMed ID: 20819124
[TBL] [Abstract][Full Text] [Related]
38. Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.
Berndt A; Büttner R; Gühne S; Gleinig A; Richter P; Chen Y; Franz M; Liebmann C
Exp Cell Res; 2014 Apr; 322(2):402-14. PubMed ID: 24394543
[TBL] [Abstract][Full Text] [Related]
39. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
